The company’s revenue climbed 14.6% to RMB 820 million, while adjusted EBITDA surged more than 4.6 times to RMB 220 million. Financial health improved alongside profitability, with gross margins widening to 36.4% and net operating cash flow turning positive in the second half of the year at RMB 29.3 million. CEO Xu Jiming attributed these results to the company's transition toward scalable, platform-based products rather than isolated project deliveries.
Driving this performance is YiduCore, the firm's proprietary healthcare AI infrastructure, which has processed nearly 9 billion medical records to date. The infrastructure supports a diverse portfolio, including AI for Medical, which secured major provincial contracts in Hainan; AI for Life Sciences, now serving 17 of the world’s top 20 pharmaceutical companies; and AI for Care, which saw revenue jump 37.6% as enrollment in supplementary insurance programs in Shenzhen and Beijing remained robust. CFO Feng Xiaoying emphasized that these gains stem from optimized business operations and improved efficiency, positioning the company to focus on high-value disease areas in the coming fiscal periods.
Comments (0)
No comments yet. Be the first!